SOPHIRIS BIO INC.
SPHS evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Lead Asset:
- topsalysin (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SPHS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
topsalysin (Phase 3)
Next Catalyst
—
Tracking 1 pipeline candidate for SOPHIRIS BIO INC..
Run SOPHIRIS BIO INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SOPHIRIS BIO INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is SOPHIRIS BIO INC.'s lead drug candidate?
SOPHIRIS BIO INC.'s most advanced tracked candidate is topsalysin (Phase 3) for intermediate risk localized prostate cancer.
Who is the CEO of SOPHIRIS BIO INC.?
Randall E. Woods is the chief executive officer of SOPHIRIS BIO INC. (SPHS).
What therapeutic areas does SOPHIRIS BIO INC. focus on?
SOPHIRIS BIO INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.